Valneva reports preliminary unaudited 2024 revenue and cash and provides 2025 outlook

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023) strong year-end cash position of €168.3 million substantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 2025 2025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic r&d investments with lower operating cash burn saint-herblain (france), february 18, 2025 – valneva se (nasdaq: valn; euronext paris: vla) a specialty vaccine company, today reported its preliminary unaudited full-year 2024 revenue and cash results1 and provided a 2025 outlook. the company will publish its 2024 audited consolidated financial statements and host an analyst call on march 20, 2025.
VALN Ratings Summary
VALN Quant Ranking